Trade Scholar Rock Holding Corp - SRRK CFD

Scholar Rock Holding Corporation Company profile

About Scholar Rock Holding Corp

Scholar Rock Holding Corporation is a biopharmaceutical company that is focused on the discovery and development of medicines for the treatment of serious diseases. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFβ1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. Its selective inhibitors of the activation of transforming growth factor-beta (TGFβ) for the treatment of fibrotic diseases. It is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFβ1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFβ1 presented by cells of the immune system.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Scholar Rock Holding Corp revenues increased 22% to $18.8M. Net loss increased 52% to $131.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 39% to $98.3M (expense), General and administrative - Balancing increase of 33% to $27.3M (expense).